Alzheimer's Disease Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Alzheimer's disease (AD) is the most common cause of dementia, accounting for 60–80% of dementia cases globally. Approximately 55 million people worldwide live with dementia, a number projected to reach 139 million by 2050 as populations age. AD is a progressive neurodegenerative disorder characterised by pathological accumulation of amyloid-beta plaques and tau neurofibrillary tangles in the brain, leading to synaptic dysfunction, neuroinflammation, and eventual neuronal death — clinically manifesting as progressive memory loss, language difficulties, impaired executive function, and ultimately loss of ability to perform daily activities.

Until 2023, all FDA-approved Alzheimer's treatments were purely symptomatic — improving cognitive symptoms temporarily without altering the underlying disease course. The landmark FDA approvals of lecanemab (Leqembi, Biogen/Eisai, 2023) and donanemab (Kisunla, Eli Lilly, 2024) — amyloid-beta targeting monoclonal antibodies — marked the first disease-modifying treatments for early-stage AD, slowing clinical decline by approximately 25–35% compared to placebo in large phase 3 trials. These represent a genuine paradigm shift, though their effect size is modest and they carry significant risks of amyloid-related imaging abnormalities (ARIA) including brain microhaemorrhages.

The comprehensive management of AD involves: (1) accurate diagnosis and staging with cognitive assessments, brain imaging (MRI, amyloid PET), and biomarker testing (CSF amyloid and tau; plasma amyloid ratio p-tau181); (2) initiation of appropriate pharmacological therapy; (3) non-pharmacological interventions (cognitive stimulation, physical exercise, sleep management, sensory engagement); (4) management of behavioural and psychological symptoms of dementia (BPSD); and (5) caregiver support and advance care planning. Given the disease's progressive nature, a gerontologist/neurologist-led multidisciplinary team is essential.

• Mild cognitive impairment (MCI) due to AD: Subjective cognitive complaints with objective evidence of mild decline without functional impairment. 10–15% of MCI patients convert to dementia annually. Lecanemab and donanemab are approved for early AD including symptomatic MCI with confirmed amyloid pathology. Intervention at this stage offers the greatest potential for disease modification.
• Mild Alzheimer's dementia: Memory problems significantly affecting daily life; preserved ability for self-care in most activities. Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) approved and effective. Disease-modifying amyloid antibodies indicated if amyloid-positive. Goal: maintain function and independence.
• Moderate Alzheimer's dementia: Increasing memory loss, confusion, difficulty recognising family members, behavioural changes (agitation, wandering, sleep disturbances). Memantine added to cholinesterase inhibitor (combination donepezil + memantine modestly superior to donepezil alone — Tariot 2004 trial). Management of BPSD: non-pharmacological approaches first; antipsychotics (risperidone, quetiapine) only for severe agitation/psychosis with regular reassessment.
• Severe Alzheimer's dementia: Loss of ability to perform basic daily activities, incontinence, loss of mobility, minimal verbal communication. Palliative and comfort-focused care predominates. Careful review of all medications — many provide minimal benefit in severe AD. Advanced care planning discussions with family regarding hospitalisation, resuscitation, artificial nutrition, and place of care (home, nursing home, hospice).
• Behavioural and psychological symptoms of dementia (BPSD): Affects 90% of AD patients at some point — agitation (45–70%), depression (30–50%), psychosis/hallucinations (20–30%), apathy (70%), sleep disturbances (40–70%). Non-pharmacological management (validation therapy, music therapy, aromatherapy, structured activities) is first-line. Pharmacological treatment reserved for severe, persistent, or safety-threatening symptoms.

Diagnostic evaluation for Alzheimer's disease:

• Comprehensive cognitive assessment: MMSE (Mini-Mental State Examination), MoCA (Montreal Cognitive Assessment), ADAS-Cog. Neuropsychological battery for detailed cognitive profiling and differentiation from other dementias
• Brain MRI to assess atrophy pattern (medial temporal lobe, hippocampal atrophy — characteristic of AD), exclude vascular lesions, normal pressure hydrocephalus, and space-occupying lesions
• Laboratory tests: thyroid function, B12, folate, CBC, metabolic panel, syphilis, HIV — to exclude reversible causes of cognitive impairment
• Amyloid biomarker confirmation — required for lecanemab and donanemab eligibility: amyloid PET scan (florbetapir, flutemetamol, florbetaben) or CSF amyloid-beta 42/40 ratio + tau (p-tau181/217). Plasma biomarkers (p-tau217 blood test) increasingly used as accessible screening tool
• Apolipoprotein E (APOE4) genotyping — APOE4 carriers have significantly higher ARIA risk with amyloid-targeting antibodies; homozygous APOE4 carriers may be advised against lecanemab/donanemab at some centres given very high ARIA risk

Eligibility for disease-modifying amyloid antibody therapy (lecanemab/donanemab):

• Confirmed symptomatic early AD (MCI or mild dementia) with amyloid pathology demonstrated on PET or CSF/plasma biomarkers
• CDR (Clinical Dementia Rating) global score 0.5–1.0
• No contraindications to MRI monitoring (required for ARIA surveillance)
• Anticoagulation — relative contraindication due to increased microhaemorrhage risk; careful individual risk-benefit assessment
• Recent stroke or active cerebrovascular disease — relative contraindication

Management of Alzheimer's Disease Treatment is individualised based on disease severity, patient age, comorbidities, and patient values. The geriatric and multidisciplinary team develops a personalised plan incorporating the following evidence-based treatment modalities:

• Conservative and lifestyle-based management: For many presentations, targeted lifestyle modification — including nutritional optimisation, graded physical activity, weight management, alcohol and smoking cessation — forms the foundation of care. Regular specialist monitoring and patient self-management education enable early detection of deterioration and empower patients to actively participate in their treatment.
• Pharmacological therapy: Evidence-based drug therapy tailored to disease mechanism and individual patient profile forms the pharmacological backbone. First-line agents are selected per current international guidelines, with treatment escalated to second-line or combination therapy for inadequate responders. Regular monitoring ensures therapeutic efficacy and detects adverse effects early.
• Procedural and interventional approaches: Where pharmacological management is insufficient or specific structural or functional abnormalities are identified, minimally invasive or interventional procedures are considered. These are performed by experienced geriatric and multidisciplinary specialists at accredited facilities with appropriate pre-procedure preparation and post-procedure monitoring protocols.
• Surgical treatment: Surgery is indicated for patients with advanced disease, complications, or conditions unresponsive to medical management. Modern surgical approaches include laparoscopic, robotic-assisted, and image-guided techniques that minimise operative morbidity and accelerate recovery. Surgical decisions are made following multidisciplinary discussion and informed consent.
• Multidisciplinary team (MDT) care: Complex presentations are managed through an MDT integrating expertise from relevant specialties — geriatric and multidisciplinary medicine, radiology, physiotherapy, nutrition, psychology, and palliative care as appropriate. MDT-driven care demonstrably improves outcomes for complex conditions. Patient and family involvement in MDT planning ensures alignment with individual values.
• Emerging and clinical trial options: Access to investigational treatments through clinical trials at specialist centres offers patients with refractory or high-risk presentations the opportunity to access next-generation therapies under systematic monitoring. Trial eligibility is assessed as part of the MDT plan.

• Symptomatic improvement with cholinesterase inhibitors: Donepezil, rivastigmine, and galantamine achieve modest but clinically meaningful stabilisation of cognitive function — slowing cognitive decline by 1–3 points on the ADAS-Cog (11-point) scale at 12 months compared to placebo in RCTs. While not curative, they provide 6–12 months of functional benefit — meaningful for patients and caregivers — and are generally well tolerated.
• Disease modification — lecanemab: CLARITY AD trial (2022): lecanemab significantly reduced clinical decline on the CDR-SB (Clinical Dementia Rating Sum of Boxes) by 27% at 18 months compared to placebo. Amyloid clearance confirmed on PET in 80% of lecanemab-treated patients vs. 0% placebo. This is the first treatment demonstrated to slow the underlying AD disease process, not just symptoms.
• Disease modification — donanemab: TRAILBLAZER-ALZ 2 trial (2023): donanemab slowed decline on the iADRS (Integrated AD Rating Scale) by 35% in participants with low-intermediate tau burden at 76 weeks. Complete amyloid clearance achieved in 76% of patients by 76 weeks — enabling cessation of infusions ('treatment stop' model). FDA approved 2024.
• Non-pharmacological benefits: Structured cognitive stimulation programmes (weekly group activities targeting memory, language, and executive function) show moderate evidence for cognitive and mood improvement. Aerobic exercise (150 minutes/week) has strongest evidence for slowing cognitive decline in MCI and early AD — multiple RCTs (EXERT, FINGER) support exercise as a core intervention. Sleep management (treating sleep apnoea, improving sleep hygiene) may slow amyloid accumulation.
• Caregiver support benefits: Structured caregiver education and support programmes reduce caregiver burden, depression, and burnout — enabling patients to remain at home longer, delaying nursing home placement by 12–18 months on average. Caregiver-directed care is one of the most cost-effective AD interventions.

• Cholinesterase inhibitor side effects: Gastrointestinal — nausea, vomiting, diarrhoea (20–30% incidence; managed by slow dose titration and taking with food); bradycardia and heart block (requires ECG before initiation in patients with pre-existing cardiac conduction abnormalities); nightmares and insomnia (donepezil — consider switching to morning dosing); urinary incontinence, muscle cramps, anorexia.
• Memantine side effects: Generally well tolerated. Dizziness, constipation, headache (5–10%). Rarely confusion (paradoxical — dose reduction resolves). Renal dose adjustment required for creatinine clearance <30 mL/min.
• ARIA (Amyloid-Related Imaging Abnormalities) — lecanemab and donanemab: The principal safety concern of amyloid antibody therapy. ARIA-E (oedema/effusions) occurs in 21–35% of lecanemab-treated patients; symptomatic ARIA-E in 2–3%. ARIA-H (microhaemorrhages/haemosiderosis) in 13–17% on lecanemab. Most ARIA events are asymptomatic and detected only on MRI monitoring; symptomatic ARIA presents as headache, confusion, visual changes, gait disturbance. Severe ARIA (grade 3–4, including rare fatal intracerebral haemorrhage) reported in <1%. APOE4 carriers (particularly homozygotes) have 2–3× higher ARIA risk. Regular MRI monitoring (every 3 months during first year of treatment) is mandatory. Anticoagulant co-use significantly increases ARIA risk.
• Management of BPSD with antipsychotics: Atypical antipsychotics (risperidone, quetiapine, olanzapine) carry an FDA Black Box warning for increased mortality (approximately 1.6–1.7× vs. placebo) and cerebrovascular adverse events in elderly patients with dementia. Use only when non-pharmacological measures have failed for severe, safety-threatening BPSD; lowest effective dose, regular review and attempt to discontinue.
• Falls risk: Cognitive impairment, sedating medications (antipsychotics, benzodiazepines), and orthostatic hypotension from cholinesterase inhibitors all increase fall risk — the leading cause of injury in AD patients. Fall risk assessment and mitigation (walking aids, home modification, medication review, physiotherapy) should be integral to AD care.

Treatment response monitoring: Following initiation of Alzheimer's Disease Treatment, clinical response is assessed at 4–12 weeks. Objective parameters (laboratory values, imaging, functional assessments) and symptom scores are tracked; treatment is adjusted based on response and tolerability.

Regular specialist review: Ongoing management requires specialist appointments every 3–6 months once stable, with more frequent reviews during treatment initiation, dose adjustment, or when complications arise. Each visit includes clinical assessment, medication review, and complication screening.

Long-term monitoring: Annual comprehensive review including laboratory investigations, imaging as indicated, quality-of-life assessment, and screening for disease-related complications. Lifelong healthy lifestyle behaviours and regular check-ins with primary care complement specialist follow-up to ensure continuity of care and early detection of any deterioration.

Alzheimer's disease imposes enormous economic costs — both direct medical costs and informal caregiver costs. The total societal cost of dementia exceeds USD 1.3 trillion globally per year (Alzheimer's Disease International, 2022). International patients and families seek affordable specialist care and medications:

• India: Neurologist/geriatrician specialist consultation: USD 15–50. Annual medication cost — donepezil generic (10 mg): USD 30–80/year in India vs. USD 800–1,200/year in USA; memantine generic: USD 50–150/year in India. Memory clinics at AIIMS, NIMHANS (Bengaluru), Apollo, and Fortis provide comprehensive cognitive assessment and specialist management. Cognitive rehabilitation and dementia day care programmes: USD 500–2,000/year. Private memory care nursing facilities: USD 3,000–8,000/year (vs. USD 60,000–120,000/year in USA). Lecanemab and donanemab: not yet accessible or approved in India at scale.
• Thailand: Memory clinic assessment and annual management: USD 2,000–5,000. Geriatric nursing home: USD 8,000–20,000/year at international standard facilities.
• United States: Lecanemab (Leqembi): USD 26,500/year WAC; donanemab (Kisunla): USD 32,000/year. Medicare covers lecanemab/donanemab for traditional Medicare beneficiaries who meet clinical criteria. Annual AD care costs including medication, specialist visits, cognitive therapy: USD 30,000–80,000 (home care) to USD 80,000–150,000+ (memory care facility).
• United Kingdom (NHS): Donepezil, rivastigmine, galantamine, and memantine available on NHS for appropriate patients. Lecanemab and donanemab not yet approved for routine NHS use pending NICE appraisal (as of mid-2026). Memory assessment services free on NHS with referral from GP.

Alternative or complementary approaches may be considered for patients unsuitable for standard Alzheimer's Disease Treatment, preferring less intensive treatment, or seeking additional options alongside conventional care:

• Watchful waiting / active surveillance: For patients with mild or stable presentations, a period of active monitoring with regular specialist review may defer treatment. This approach is appropriate only when disease trajectory is slow and quality of life is maintained, with clear pre-defined triggers for initiating active treatment.
• Evidence-based complementary approaches: Structured exercise programmes, dietary interventions, mindfulness-based stress reduction, sleep optimisation, and physiotherapy may complement conventional treatment or provide symptomatic benefit. All complementary approaches should be discussed with the treating specialist to ensure no interactions with ongoing treatments.
• Alternative specialist or second opinion: Patients who have not responded to initial treatment may benefit from referral to a specialist with higher subspecialty expertise or a tertiary centre with access to advanced techniques and clinical trials. A formal second opinion from an experienced specialist is always appropriate before major treatment decisions.
• Clinical trial participation: For refractory or advanced presentations, clinical trials at specialist centres offer access to investigational therapies not yet in routine use — including novel pharmacological agents, targeted biologics, and innovative procedures. Trial costs for experimental components are typically borne by the sponsor.
• Palliative and supportive care: When curative or disease-modifying treatment is not appropriate or desired, specialist palliative care maximises quality of life through expert symptom control, psychological and spiritual support, and coordinated care. Modern palliative medicine can be delivered alongside active treatment at any disease stage and consistently improves patient wellbeing.